RJFSA
VIVO

Raymond James Financial Services Advisors’s Meridian Bioscience Inc VIVO Stock Holding History

Raymond James Financial Services Advisors’s Portfolio VIVO Stock Details VIVO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-44,074
Closed -$848K – 3474
2021
Q3 		$848K Buy
44,074
+499
+1% +$9.95K ﹤0.01% 2069
2021
Q2 		$966K Buy
+43,575
New +$924K ﹤0.01% 1971

Other funds holding VIVO

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
EARNEST Partners
EARNEST Partners Atlanta, Georgia $24.3B AUM 34.41% 1-Year Est. Return
RA
Royce & Associates New York $10.1B AUM 42.88% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
VLKIM
Van Lanschot Kempen Investment Management Amsterdam, Netherlands $11.4B AUM 16.77% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
SFM
Systematic Financial Management Teaneck, New Jersey $4.36B AUM 40.56% 1-Year Est. Return

Raymond James Financial Services Advisors's VIVO Position: Q4 2021 in Review

Raymond James Financial Services Advisors sold out of Meridian Bioscience Inc (VIVO) in Q4 2021, closing a stake of 44,074 shares — an estimated $848K sold.

Raymond James Financial Services Advisors first reported a position in VIVO in Q2 2021 and held it in 2 quarters. The position peaked at $966K in Q2 2021. 180 funds tracked by Wall St. Rank hold VIVO as of Q4 2021.

  • Raymond James Financial Services Advisors reported no remaining Meridian Bioscience Inc position as of Q4 2021 after selling out during the quarter.
  • Raymond James Financial Services Advisors sold 44,074 Meridian Bioscience Inc shares in Q4 2021, an estimated $848K.
  • Raymond James Financial Services Advisors first reported a position in Meridian Bioscience Inc in Q2 2021 and held it in 2 quarters.
  • Raymond James Financial Services Advisors's Meridian Bioscience Inc position peaked at $966K in Q2 2021.
  • 180 funds tracked by Wall St. Rank held Meridian Bioscience Inc as of Q4 2021.

Based on Raymond James Financial Services Advisors's 13F filing for Q4 2021, filed 8 Feb 2022.